neurology

News

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona

UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.

R&D

Neuroplasticity modulators as innovative potential disease-m...

In September last year, we reported Servier had advanced its emerging neurology pipeline into the clinical trials stage by licensing a drug for the rare genetic disorder Fragile X syndrome

News

Most patients "won't see benefit" with Alzheimer's drugs

A review of clinical data on amyloid-targeting Alzheimer's therapies has found absent or trivial efficacy, but is facing pushback from some experts.

R&D

Female neuroscientist surveys brain scans

From genetic insight to Phase 3: What rare neurology require...

Rare neurology is not defined by a lack of scientific opportunity or capital.

News

Lundbeck preps phase 3 for migraine prevention drug

Lundbeck seems to have brought its migraine prevention drug bocunebart back on track with positive data for an intravenous formulation.

News

Data builds on Roche's dominance in primary progressive MS

Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona

Neuroplasticity modulators as innovative potential disease-m...

Most patients "won't see benefit" with Alzheimer's drugs

From genetic insight to Phase 3: What rare neurology require...

Lundbeck preps phase 3 for migraine prevention drug

Data builds on Roche's dominance in primary progressive MS

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

neurology

Editor's Picks